Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Depressive Disorder, Major
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is a stratified, parallel-group, single-center study utilizing multimodal imaging techniques to identify biomarkers for Major Depressive Disorder (MDD). The study goal is to identify biomarkers for MDD and treatment response that can be implemented in clinical diagnosis and care as valid and reliable measures, through monitoring neurophysiological and electrophysiological changes across the course of transcranial magnetic stimulation (TMS) treatment.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Device: rTMS therapy — rTMS treatment parameters will be determined by TMS care providers. Typical TMS settings for MDD involve rTMS applied at 10 Hz with an intensity of 120 % of resting motor threshold. Forty trains of 4 s duration with 11s of trains is typically applied (3000 pulses per day), resulting in approximately 90,000 pulses in a given treatment course.

Primary Outcomes

  • Change in MADRS score from baseline to end of treatment (Up to one month prior to initial TMS session (baseline) to within one month following the completion of TMS treatment (~ 8 weeks))
  • Change in resting state BOLD signal from baseline to end of treatment (Up to one month prior to initial TMS session (baseline) to within one month following the completion of TMS treatment (~ 8 weeks))
  • Change in resting state EEG from baseline to end of treatment (Up to one month prior to initial TMS session (baseline) to within one month following the completion of TMS treatment (~ 8 weeks))
  • Change in white matter integrity from baseline to end of treatment (Up to one month prior to initial TMS session (baseline) to within one month following the completion of TMS treatment (~ 8 weeks))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2020-12-01
Completion: 2027-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, San Francisco
Principal Investigators:
  • Andrew Krystal, MD, MS (PRINCIPAL_INVESTIGATOR) - University of California, San Francisco
Contact Information
Study Contact:
Katherine Scangos, MD, PhD
415-476-7439
brainstim@ucsf.edu
Rebecca Martinez, MS
rebecca.martinez@ucsf.edu
Katherine Scangos, MD, PhD
415-476-7439
trdepression@ucsf.edu
University of California, San Francisco
Interventions
  • Device: rTMS therapy — rTMS treatment parameters will be determined by TMS care providers. Typical TMS settings for MDD involve rTMS applied at 10 Hz with an intensity of 120 % of resting motor threshold. Forty trains of 4 s duration with 11s of trains is typically applied (3000 pulses per day), resulting in approximately 90,000 pulses in a given treatment course.
Study Locations (1 sites)
University of California, San Francisco, San Francisco, California 94143 United States
Eligibility Criteria
Inclusion Criteria: * Age 18-70 * Meet Diagnostic and Statistical Manual-V (DSM-V) diagnostic criteria for Major Depressive Disorder in a current major depressive episode, without psychotic features. * Has Montgomery-Asberg Depressive Rating Scale (MADRS) of \> 19 at baseline, corresponding with moderate to severe depression. * Demonstrate a moderate level of resistance to antidepressant treatment in the current episode, defined as a failure of 1-4 adequate medication trials. * If participant is on a regimen of psychotropic medication, no changes in this regimen should be made during the period between the time at which pre-treatment and post-treatment scans are taken. * Willing and able to undergo non-invasive brain stimulation * Willing and able to attend research visits for approximately 8 weeks * Willing and able to provide informed consent * Ability to speak and read English Exclusion Criteria: * Diagnosed with acute or chronic psychotic symptoms of disorders (e.g. schizophrenia, schizophreniform, schizoaffective disorder) in the current depressive episode. * Has neurological conditions including epilepsy, cerebrovascular disease, dementia, increased intracranial pressure, having a history of repetitive or severe head trauma, or with primary or secondary tumors in the central nervous system. * Presence of an implanted magnetic-sensitive medical device in or near the head, including but not limited to pacemaker, vagus nerve stimulator, or metal aneurysm clips or coils, staples, or stents. * Generalized anxiety disorder as the primary DSM-V disorder during the current MDD episode. * Meets criteria for alcohol or substance abuse or dependence (other than caffeine) in previous 6 months, as determined by the SCID * History of seizures * Implantable hardware not compatible with MRI or with the study * Inability to comply with study daily visits * Women who are pregnant, plan to become pregnant, or breast feeding * Inability to speak and/or read English * Inability to give consent * Any active suicidal intent or plan during the current depressive episode, as determined by a score of 3 on Question #9 of Beck's Depression Inventory (scores reviewed daily by study team members versed in scoring clinical scales), or as by a subjective determination by a study clinician during any study visit.
Conditions Primary Open Angle Glaucoma
Phase NA
Enrollment 545
Locations 22 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this post-approval study is to evaluate the rate of Hydrus Microstent malposition and associated clinical sequelae occurring within 24 months post-operation. Qualified subjects will undergo uncomplicated cataract surgery with placement of a monofocal intraocular lens (IOL), followed by implantation of the Hydrus Microstent.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Hydrus Microstent — Crescent-shaped nitinol device intended as a permanent implant to provide an outflow pathway for aqueous humor. The device is placed through the trabecular meshwork into Schlemm's canal immediately following placement of a monofocal IOL.
  • Procedure: Cataract surgery — Cataract surgery performed using standard anesthesia and phacoemulsification techniques
  • Device: Monofocal IOL — Commercially available monofocal intraocular lens as determined by the investigator

Primary Outcomes

  • Rate of occurrence of clinically significant device malposition associated with clinical sequelae (Day 0 operative, up to Month 24 postoperative)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2020-08-25
Completion: 2028-10
Eligibility
Age: 45 Years and older
Sex: ALL
Volunteers: false
Enrollment: 545 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Alcon Research
Principal Investigators:
  • Clinical Project Lead, CDMA Surgical (STUDY_DIRECTOR) - Alcon Research
Contact Information
Study Contact:
Alcon Call Center
1-888-451-3937
alcon.medinfo@alcon.com
Interventions
  • Device: Hydrus Microstent — Crescent-shaped nitinol device intended as a permanent implant to provide an outflow pathway for aqueous humor. The device is placed through the trabecular meshwork into Schlemm's canal immediately following placement of a monofocal IOL.
  • Procedure: Cataract surgery — Cataract surgery performed using standard anesthesia and phacoemulsification techniques
  • Device: Monofocal IOL — Commercially available monofocal intraocular lens as determined by the investigator
Study Locations (22 sites)
Coastal Vision, Irvine, California 92618 United States
Sacramento Eye Consultants, Sacramento, California 95815 United States
Eye Center of Northern Colorado, Loveland, Colorado 80538 United States
Jones Eye Center PC, Sioux City, Iowa 51104 United States
Stiles Eyecare Excellence Cataracts and Glaucoma, Overland Park, Kansas 66213 United States
Visionary Eye Doctors, Rockville, Maryland 20852 United States
Fraser Eye Care Center, Fraser, Michigan 48026 United States
Twin Cities Eye Consultants, Coon Rapids, Minnesota 55433 United States
Midwest Vision Research Foundation, Chesterfield, Missouri 63017 United States
Moyes Eye Center, Kansas City, Missouri 64154 United States
Eligibility Criteria
Inclusion Criteria: * An operable, age-related cataract with best corrected visual acuity (BCVA) of 20/40 or worse; * Diagnosis of primary open angle glaucoma treated with no more than 4 topical hypotensive medications; * Optic nerve appearance characteristic of glaucoma; * Medicated IOP less than or equal to 31 millimeters mercury (mmHg); Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Closed angle forms of glaucoma; * Congenital or developmental glaucoma; * Secondary glaucoma; * Use of more than 4 ocular hypotensive medications; * Previous argon laser trabeculoplasty, trabeculectomy, tube shunts, or any other prior filtration or cilioablative surgery; * Prior surgery with implanted device or other surgery involving the trabecular meshwork or Schlemm's canal; * Other protocol-defined exclusion criteria may apply.
Conditions Breast Cancer
Phase PHASE2
Enrollment 44
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a Phase II randomized, controlled, open label breast cancer clinical trial. 66 patients will be enrolled. The drugs being studied are hydroxychloroquine (Plaquenil) and abemaciclib (also Verzenio). This research study is testing whether using these drugs to target the disseminated tumor cells in bone marrow can reduce their number or eliminate them. Both hydroxychloroquine and abemaciclib are pills that will be taken twice daily. Both are approved by the FDA

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Abemaciclib — Oral CDK4/6 inhibitor to target bone marrow disseminated tumor cells (DTCs)
  • Drug: Hydroxychloroquine — Oral autophagy inhibitor to target bone marrow disseminated tumor cells (DTCs)

Primary Outcomes

  • Incidence of treatment-emergent adverse events during cycle 1 of the safety cohort (safety of combination HCQ + Abema) (Toxicity is assessed over the first cycle (4 weeks) of treatment)
  • Change in bone marrow DTC number evaluated by DTC-IHC assay after 6 cycles of therapy compared to baseline (Efficacy of Abema +/- HCQ in eliminating bone marrow DTCs) (6 cycles (approximately 6 months))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2021-11-01
Completion: 2028-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 44 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Abramson Cancer Center at Penn Medicine
Principal Investigators:
  • Amy Clark, MD (PRINCIPAL_INVESTIGATOR) - Abramson Cancer Center at Penn Medicine
Contact Information
Study Contact:
Lauren Bayne, PhD
215-615-2367
breastcancerclinicaltrials@pennmedicine.upenn.edu
Lauren Bayne, PhD
215-615-2367
breastcancerclinicaltrials@pennmedicine.upenn.edu
Abramson Cancer Center of the University of Pennsylvania
Amy Clark, MD
Abramson Cancer Center of the University of Pennsylvania
Interventions
  • Drug: Abemaciclib — Oral CDK4/6 inhibitor to target bone marrow disseminated tumor cells (DTCs)
  • Drug: Hydroxychloroquine — Oral autophagy inhibitor to target bone marrow disseminated tumor cells (DTCs)
Study Locations (1 sites)
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania 19104 United States
Eligibility Criteria
Inclusion Criteria: * Histologically-confirmed, primary, invasive breast cancer diagnosed within 5 years of entry into the companion DTC screening protocol UPCC 28115 * Qualifying risk status, at diagnosis utilizing receptor testing by ASCO/CAP guidelines, meting at least one of the following: (i) Lymph node involvement a. Pathologically-confirmed positive axillary lymph nodes, regardless of receptors, or (b) Evidence of lymph node involvement by preoperative imaging AND fibrosis and/or treatment effect in lymph nodes after neoadjuvant therapy, regardless of receptor status (ii) Primary tumor that is ER/PR/Her2 negative: estrogen receptor (ER) \< 10%, progesterone receptor (PR) \< 10% and negative for Her2-overexpression by ASCO-CAP guidelines, regardless of lymph nodes status (iii) Primary tumor that is ER+/Her2 negative/Lymph node negative with Breast Cancer Recurrence Score of \>/= 25 per the Genomic Health Oncotype DX breast cancer test and/or high risk MammaPrint (iv) Evidence of residual disease in the breast on pathologic assessment after neoadjuvant chemotherapy * Patients must have completed all primary therapy (definitive surgery, (neo)adjuvant chemotherapy adjuvant radiation and/or Her2-directed therapy) for the index malignancy at least 4 weeks prior to study entry. Prior treatment-related toxicity must be resolved or improving to Grade 1 with the exception of alopecia, Grade 2 endocrine disorders (e.g. adrenal insufficiency or thyroid disorders from prior immunotherapy) controlled on stable replacement therapy for \> 1 year, and up to Grade 3 peripheral neuropathy, prior to study enrollment. Concurrent receipt of adjuvant endocrine and bone modifying agents is allowed per standard of care guidelines. Tamoxifen is not allowed due to drug-drug interactions with HCQ. * Bone marrow aspirate obtained via research trial UPCC 28115 after completion of therapy (except endocrine therapy) demonstrates detectable DTCs (via IHC) * No evidence of recurrent local or distant breast cancer by physical examination, blood tests (CBC, LFTs, Alk Phos), or imaging. Assessment for overt metastatic disease by radiologic testing per institutional guidelines (CT Chest, Abdomen and Pelvis, bone scan, MRI and/or PET/CT) will only be done in patients with DTCs detected on bone marrow aspirate who are being screened for this trial. * Age \>/= 18 years * ECOG performance status =/\< 2 * Ability to swallow oral medications * No contraindications to the study medications or uncontrolled medical illness. * Adequate bone marrow function as shown by: ANC \>/= 1.5 x 10\^9/L, Platelets \>/= 100 x 10\^9/L, Hb \>9 g/dL * Adequate liver function as shown by: Serum bilirubin \</= 1.5 x ULN, ALT and AST \</= 3.0 x ULN, and INR \</=1.5 * Adequate renal function: serum creatinine \</= 1.5 x ULN * Adequate muscle function: creatinine phosphokinase (CPK) \</= 2.5 x ULN * Anticoagulation is allowed if target INR =/\< 1.5 on a stable dose of warfarin or on a stable dose of anticoagulant for \>2 weeks at time of randomization * Ability to provide informed consent Exclusion Criteria * Concurrent enrollment on another investigational therapy * Patient has received an experimental treatment in a clinical trial within the last 30 days or 5 half-lives, whichever is longer, prior to randomization (or treatment assignment), or is currently enrolled in any other type of medical research (for example: medical device) judged by the sponsor not to be scientifically or medically compatible with this study. * Prior treatment with abemaciclib is not allowed. (Patients may have received prior CDK4/6 inhibitor therapy with an agent other than abemaciclib. Patients must have discontinued CDK4/6 inhibitor at least 6 months prior to screening.) * Known hypersensitivity to hydroxychloroquine or any of its derivatives * Prior hydroxychloroquine exposure for a duration of \> 1 month since the completion of the patient's primary therapy (definitive surgery, (neo)adjuvant chemotherapy, adjuvant radiation, and/or Her2-directed therapy) for the index malignancy. * Patients with hormone-receptor positive breast cancer may not be receiving tamoxifen due to drug-drug interactions with hydroxychloroquine * Patients who have initiated bone modifying agents within 3 months prior to the start of study treatment * Patients who have had major surgery within 14 days prior to randomization (or treatment assignment) * Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study * Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods. * Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose of Abema
Conditions Asthma
Phase NA
Enrollment 92
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

According to the definition provided by the GINA guidelines, asthma is characterized by a variable and reversible limitation of expiratory airflow and by the following symptoms: wheezing, dyspnoea, thoracic constriction and/or cough. The type and the severity of airflow limitation can vary over time (1) depending on external agents, such as physical exercise, polluting agents, climate changes and viral infections. The therapy is mainly based on the use of inhaled corticosteroids and bronchodilators. Patients affected by severe asthma (\~ 10% of total prevalence of asthma and at high risk of exacerbations and/or hospitalization) may not control their symptoms, even if exposed to maximal doses of inhalation therapy.The behavioural sciences can potentially help to find the psychological factors behind scarce adherence and to develop strategies with the aim of improving the interactive processes between patients, medical doctors and health care professionals

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: multidisciplinary lessons — the multidisciplinary lessons will be conducted by study staff, formed by pneumologist, nurse, biologist and respiratory therapist once a week within 1 month after randomization. Study staff will deal with the following topics: asthma physiopathology, recognition of asthma symptoms and exacerbation, educational interventions on therapy and device, nutritional counselling if necessary. Patients will receive a paper diary for symptoms and an expiratory pick flow meter (PFM) to be done twice a day

Primary Outcomes

  • number of exacerbations (2 years)
  • ER accesses (2 years)
  • number of asthma related hospitalizations (2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2019-04-01
Completion: 2026-12-15
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 92 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Istituti Clinici Scientifici Maugeri SpA
Principal Investigators:
  • Antonio Spanevello, Prof (PRINCIPAL_INVESTIGATOR) - ICS Maugeri
Contact Information
Study Contact:
Dina Visca, Prof.
0331829599
dina.visca@icsmaugeri.it
Dina Visca
+390331829409
dina.visca@icsmaugeri.it
Istituti Clinici Maugeri Pneumologia
Francesca Cherubino
+390331829599
francesca.cherubino@icsmaugeri.it
Istituti Clinici Maugeri Pneumologia
Interventions
  • Behavioral: multidisciplinary lessons — the multidisciplinary lessons will be conducted by study staff, formed by pneumologist, nurse, biologist and respiratory therapist once a week within 1 month after randomization. Study staff will deal with the following topics: asthma physiopathology, recognition of asthma symptoms and exacerbation, educational interventions on therapy and device, nutritional counselling if necessary. Patients will receive a paper diary for symptoms and an expiratory pick flow meter (PFM) to be done twice a day
Study Locations (1 sites)
Istituti Clinici Maugeri Pneumologia, Tradate, Lombardy 21049 Italy
Eligibility Criteria
Inclusion Criteria: * Asthma diagnosis according to GINA / ATS guidelines. * Age ≥18 years Exclusion Criteria: •cognitive impairment
Conditions Breast Cancer, Triple Negative Breast Ca...
Phase PHASE2
Enrollment 110
Locations 15 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The names of the study interventions involved in this study are: * Sacituzumab govitecan (Trodelvy™;IMMU-132) * Pembrolizumab (Keytruda®; MK-3475)

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Sacituzumab Govitecan — Intravenous Infusion
  • Drug: Pembrolizumab — Intravenous Infusion

Primary Outcomes

  • Progression Free Survival (PFS) (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2020-07-20
Completion: 2029-04-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 110 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Dana-Farber Cancer Institute
Collaborators: Gilead Sciences, Merck Sharp & Dohme LLC
Principal Investigators:
  • Ana C Garrido-Castro, MD (PRINCIPAL_INVESTIGATOR) - Dana-Farber Cancer Institute
Contact Information
Study Contact:
Ana C Garrido-Castro, MD
617-632-6409
Ana_Garrido-Castro@dfci.harvard.edu
K.M. Steve Lo, MD
slo@stamhealth.org
Stamford Hospital
K.M. Steve Lo, MD
Stamford Hospital
Interventions
  • Drug: Sacituzumab Govitecan — Intravenous Infusion
  • Drug: Pembrolizumab — Intravenous Infusion
Study Locations (15 sites)
Stamford Hospital, Stamford, Connecticut 06904 United States
Miami Cancer Institute at Baptist Health (Kendall), Miami, Florida 33176 United States
Miami Cancer Institute at Baptist Health, Plantation, Florida 33324 United States
University of Chicago Medical Center, Chicago, Illinois 60637 United States
Eastern Maine Medical Center, Brewer, Maine 04412 United States
Dana Farber Cancer Institute, Boston, Massachusetts 02215 United States
DFCI @ Foxborough, Foxborough, Massachusetts 02035 United States
DFCI @ Milford Regional Hospital, Milford, Massachusetts 01757 United States
DF/BWCC in Clinical Affiliation with South Shore Hospital, South Weymouth, Massachusetts 02190 United States
The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 United States
Eligibility Criteria
Inclusion Criteria: * Participants must have histologically or cytologically confirmed invasive breast cancer with unresectable locally advanced or metastatic disease. Participants without pathologic or cytologic confirmation of metastatic disease should have unequivocal evidence of metastasis from physical examination or radiologic evaluation. * Estrogen-receptor and progesterone-receptor expression both ≤ 5% by immunohistochemistry (IHC), and HER2-negative status as determined by the current ASCO/CAP guidelines. If a patient has more than one histological result, the most recent sample will be considered for inclusion. * Participants must have PD-L1-negative metastatic breast cancer defined as less than 1% expression of PD-L1 on tumor-infiltrating immune cells (IC) by the PD-L1 IHC SP142 assay or a Combined Positive Score (CPS) less than 10 by the PD-L1 IHC 22C3 assay measured with standard of care testing. * Participants must be treatment-naïve in the metastatic setting. * Participants must have evaluable or measurable disease per RECIST 1.1. Patients with bone only disease will be allowed to participate. * Participants must agree to undergo a research biopsy, if tumor is safely accessible, at baseline. Previously collected archival tissue will also be obtained on all participants. Tissue needs to be located and availability confirmed at time of registration (see Section 9 for more details). Participants must agree to a mandatory repeat biopsy 3-6 weeks after starting treatment, if tumor is safely accessible. * Prior chemotherapy: Participants must have received no prior chemotherapy for metastatic breast cancer and must have discontinued all chemotherapy at least 28 days prior to study treatment initiation. No prior irinotecan or topoisomerase I-containing antibody drug conjugates in the metastatic or neo/adjuvant setting are allowed. All toxicities related to prior chemotherapy must have resolved to CTCAE v5.0 grade 1 or lower, unless otherwise specified per protocol, except alopecia can be any grade and neuropathy can be grade 2 or lower. * Prior biologic therapy: Patients must have received no prior biologic therapy for metastatic breast cancer and discontinued all biologic therapy at least 28 days prior to study treatment initiation. All toxicities related to prior biologic therapy must have resolved to CTCAE v5.0 grade 1 or lower, unless otherwise specified per protocol. * Prior radiation therapy: Patients may have received prior radiation therapy. Radiation therapy must be completed at least 7 days prior to study treatment initiation, and all toxicities related to prior radiation therapy must have resolved to CTCAE v5.0 grade 1 or lower, unless otherwise specified per protocol. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease. * Previously treated brain metastases are permitted, with the following provisions: * Prior SRS should complete ≥ 7 days before study treatment initiation * Prior WBRT should complete ≥ 7 days before study treatment initiation. * Any corticosteroid use for brain metastases must have been discontinued for ≥ 7 days prior to study treatment initiation. * The subject is ≥ 18 years old. * ECOG performance status 0-1 (Karnofsky \> 60%, see Appendix A). * Participants must have normal organ and marrow function as defined below: * Absolute neutrophil count ≥1,000/mcL * Platelets ≥100,000/mcL * Hemoglobin ≥ 9.0 g/dl * INR/PT/aPTT ≤1.5 × ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is in therapeutic range of anticoagulant * Total bilirubin ≤1.5 × institutional upper limit of normal (ULN)(or ≤2.0 x ULN in patients with documented Gilbert's Syndrome) * AST(SGOT)/ALT(SGPT) ≤2.5 × institutional ULN or ≤5 × institutional ULN for participants with documented liver metastases * Serum creatinine ≤1.5 × institutional ULN OR creatinine clearance ≥ 30 mL/min/ 1.73m2 for participants with creatinine levels above institutional ULN. * Female subjects of childbearing potential must have a negative serum or urine pregnancy test within 2 weeks prior to study treatment initiation. Childbearing potential is defined as participants who have not reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause) and have not undergone surgical sterilization (removal of ovaries and/or uterus). * Women of childbearing potential (WOCBP) must agree to use an adequate method of contraception. Contraception is required starting with the first dose of study medication through 180 days (6 months) after the last dose of study medication. Examples of contraceptive methods with a failure rate of \< 1% per year include bilateral tubal ligation, male sterilization, established and proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. * Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of study treatment with pembrolizumab and 3 months after the last dose of study treatment * Participants on bisphosphonates or RANK ligand inhibitors may continue receiving therapy during study treatment and also may initiate therapy with these agents on study if clinically indicated. * The participant must be capable of understanding and complying with the protocol and willing to sign a written informed consent document. Exclusion Criteria: * Has received prior systemic anti-cancer therapy, including investigational agents, within 4 weeks of study treatment initiation or during the course of this study (bisphosphonates and RANK ligand inhibitors are allowed). * Prior therapy with any anti-PD-1, PD-L1, or PD-L2 agent or sacituzumab govitecan (IMMU-132). Prior therapy with irinotecan or topoisomerase I-containing antibody drug conjugates at any time for early stage or metastatic disease. * Prior hypersensitivity to pembrolizumab or the excipients of pembrolizumab or sacituzumab govitecan (IMMU-132 therapy). * Known history of UDP-glucuronosyltransferase 1A1 (UGT1A1) \*28 allele homozygosity, which is associated with increased risk for neutropenia and diarrhea related to irinotecan. Note: Concurrent administration of strong UGT1A1 inhibitors or inducers is not allowed during the course of the study. * Known brain metastases that are untreated, symptomatic, or require therapy to control symptoms. * Major surgery within 2 weeks prior to study treatment initiation. Patients must have recovered from any effects of any major surgery. * Uncontrolled, significant intercurrent or recent illness including, but not limited to, ongoing or active infection, uncontrolled non-malignant systemic disease, uncontrolled seizures, or psychiatric illness/social situation that would limit compliance with study requirements in the opinion of the treating investigator. * Participant has a medical condition that requires chronic systemic steroid therapy (\> 10 mg of prednisone daily or equivalent) or any other form of immunosuppressive medication (including disease modifying agents) and has required such therapy in the last 2 years. Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic therapy. * Participant has documented history of autoimmune disease or syndrome that currently requires systemic steroids or immunosuppressive agents. * History of (non-infectious) pneumonitis that required steroids or current pneumonitis. * Individuals with a history of a second malignancy are ineligible except for the following circumstances. Individuals with a history of other malignancies are eligible if they have been disease-free for at lea
Conditions Gastric Cancer, Invasive Breast Cancer, ...
Phase NA
Enrollment 70
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This research is being done to determine the safety and feasibility of using a type of radiation guided by magnetic resonance imaging (MRI) and chemotherapy to treat patients with gastric and breast cancer. The name of the radiation machine involved in this study is the MRIdian Linear Accelerator.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Viewray MRIdian® Linac — MR-image guided radiation will be administered per disease site standards.

Primary Outcomes

  • Number of Patients and delivering MR-image guided radiation-Phase I (5 weeks)
  • Tumor Assessment with MR Guidance-Phase I (5 weeks)
  • Patient reported outcomes (PROMs) -Phase II (1 year)
  • 1-year tumor control-Phase II (1 year)
  • Rate of Pathologic complete response-Gastric (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-05-01
Completion: 2029-06-18
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 70 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Brigham and Women's Hospital
Principal Investigators:
  • Raymond Mak, MD (PRINCIPAL_INVESTIGATOR) - Dana-Farber Cancer Institute
Contact Information
Study Contact:
Raymond Mak, MD
6177328651
rmak@partners.org
Raymond Mak, MD
Brigham & Women's Hospital
Raymond Mak, MD
Brigham & Women's Hospital
Interventions
  • Radiation: Viewray MRIdian® Linac — MR-image guided radiation will be administered per disease site standards.
Study Locations (2 sites)
Brigham & Women's Hospital, Boston, Massachusetts 02115 United States
Dana Farber Cancer Institute, Boston, Massachusetts 02115 United States
Eligibility Criteria
Inclusion Criteria: * Participants must have histologically or cytologically confirmed malignancy requiring radiation * Age 18 years of older * ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A) * Ability to understand and the willingness to sign a written informed consent document. * Any further criteria listed in the specific disease site cohort Exclusion Criteria * History of allergic reactions attributed to gadolinium-based IV contrast \-- Note: If patient will not receive contrast, this is not applicable and kidney function will not affect eligibility * Severe claustrophobia or anxiety * Participants who cannot undergo an MRI * Any other exclusion criteria listed in the specific disease site cohort
Conditions Breast Cancer, Hypofractionation, Radiot...
Phase NA
Enrollment 1018
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

We at PGIMER have been practicing hypofractionated radiotherapy in breast cancer patients for the last 4 decades. Our standard doses have been 35Gy/15#/3wks to the chest wall after mastectomy and 40Gy/16#/3wks after breast conserving surgery (BCS).It is also a routine practice in the UK and in a few centers in Canada. Hypofractionation reduces treatment time to half while maintaining cosmesis and gives control rates equal to conventional fractionation. As breast cancer is a leading cancer in females and radiation therapy is an important part of its local management, hypofractionation helps radiation centers worldwide to meet the growing need for radiation treatment in breast cancer, particularly in developing countries where resources are limited. It also reduces the financial burden on the patient and family. In this study we want to evaluate the impact of reducing the treatment duration from 3 weeks to 1 week. Eligible patients with breast cancer after mastectomy or BCS will be treated with a radiotherapy dose of 26Gy in 5 fractions over 1 week in the study arm and 40Gy in 15 fractions over 2 weeks in the control arm. The primary endpoint of this noninferiority study will be locoregional tumour control. Secondary endpoints will be early and late radiation toxicities, quality of life, contralateral primary tumours, regional and distant metastases, survival and second cancers. A total of 1018 patients will be randomised (1:1) to receive 1 week or 2 weeks of radiotherapy. An event-driven analysis will be performed after at least 94 patients have documented locoregional recurrences.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: 1 week RT — RT will be delivered over 1 week
  • Radiation: 2 week RT — RT will be delivered over 2 week

Primary Outcomes

  • Loco-regional recurrence, Change is being assessed (5, 10 and 15 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-03-30
Completion: 2028-08-20
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 1018 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh
Principal Investigators:
  • BUDHI S YADAV (PRINCIPAL_INVESTIGATOR) - Post Graduate Institute of Medical Education and Research, Chandigarh
Contact Information
Study Contact:
BUDHI S YADAV, MD
9815981176
drbudhi@gmail.com
BUDHI S YADAV
9815981176
drbudhi@gmail.com
BUDHI SINGH YADAV
9815981176
drbudhi@gmail.com
Budhi Singh Yadav
Interventions
  • Radiation: 1 week RT — RT will be delivered over 1 week
  • Radiation: 2 week RT — RT will be delivered over 2 week
Study Locations (1 sites)
Budhi Singh Yadav, Chandigarh, 160012 India
Eligibility Criteria
Inclusion Criteria: 1. Age ≥18 years 2. Female or male 3. Invasive carcinoma of the breast 4. Breast conserving surgery(BCS) with axillary clearance or total mastectomy with axillary clearance(TMAC); (reconstruction allowed but not with implant; tissue expanders with distant metal ports are allowed) 5. Concurrent trastuzumab and hormone therapy is allowed 6. Axillary staging and/or dissection 7. Complete microscopic excision of primary tumour 8. pT3-4pN2-3 M0 disease 9. Clinical stage III disease or pathological node positive if they have received neo-adjuvant chemotherapy. 10. Written informed consent 11. Able to comply with follow-up Exclusion Criteria: 1. Supraclavicular node or internal mammary node or distant metastasis 2. Past history of malignancy except (i) basal cell skin cancer and CIN cervix uteri or(ii) non-breast malignancy allowed if treated with curative intent and at least 5 years disease free 3. Contralateral breast cancer, including DCIS, irrespective of date of diagnosis 4. Breast reconstruction using implants 5. Pregnancy 6. Concurrent cytotoxic chemotherapy(sequential neoadjuvant or adjuvant cytotoxic therapy allowed)
Conditions Breast Cancer, Neoadjuvant Therapy, Lymp...
Phase Not Applicable
Enrollment 549
Locations 35 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Today, the majority of clinically node positive (cN+) breast cancer patients is treated with neoadjuvant systemic therapy (NST). Axillary staging and treatment after NST in cN+ patients are areas of controversy. Patients with a pathological complete response (pCR) of the axillary lymph nodes are not expected to benefit from axillary lymph node dissection (ALND). Hence, less invasive axillary staging procedures are being introduced to avoid unnecessary ALND. However, evidence supporting the safety of replacing ALND by less invasive techniques in terms of oncologic safety and impact on quality of life (QoL) is lacking.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Disease free survival (DFS) (5 years)
  • Breast cancer specific survival (BCSS) (5 years)
  • Overall survival (OS) (5 years)
  • Axillary recurrence rate (ARR) (5 years)
  • Quality of life, as measured by EQ-5D-5L (Baseline, and 1 and 5 years after baseline)
  • Quality of life, as measured by Quality of Life Questionnaire Core 30 Items (QLQ-C30) and QLQ-BR23 (Baseline, and 1 and 5 years after baseline)
  • Quality of life, as measured by BREAST-Q, which includes the following domains: satisfaction with breasts, psychosocial well being, physical well being, sexual well being. (Baseline, and 1 and 5 years after baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2020-07-16
Completion: 2027-07-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 549 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Maastricht University Medical Center
Collaborators: Erasmus Medical Center, The Netherlands Cancer Institute
Principal Investigators:
  • Marjolein Smidt, MD, PhD (PRINCIPAL_INVESTIGATOR) - Maastricht University Medical Center
  • Marie-Jeanne Vrancken Peeters, MD, PhD (PRINCIPAL_INVESTIGATOR) - The Netherlands Cancer Institute
  • Linetta Koppert, MD, PhD (PRINCIPAL_INVESTIGATOR) - Erasmus Medical Center
Contact Information
Study Contact:
Sabine de Wild, MD
+31433881574
s.dewild@maastrichtuniversity.nl
Janine Simons, MD, PhD
j.simons@maastrichtuniversity.nl
Interventions
N/A
Study Locations (35 sites)
Jeroen Bosch Hospital, 's-Hertogenbosch, Netherlands
Northwest Clinics, Alkmaar, Netherlands
The Netherlands Cancer Institute, Amsterdam, Netherlands
Gelre Hospital, Apeldoorn, Netherlands
Rijnstate Hospital, Arnhem, Netherlands
Red Cross Hospital, Beverwijk, Netherlands
Alexander Monro Hospital, Bilthoven, Netherlands
Amphia Hospital, Breda, Netherlands
Van Weel-Bethesda, Dirksland, Netherlands
Slingeland Hospital, Doetinchem, Netherlands
Eligibility Criteria
Inclusion Criteria: * Female patient with unilateral invasive breast cancer and cN1-3 * Pathologically proven positive axillary lymph node * Planned to undergo neoadjuvant chemotherapy (± immunotherapy), followed by staging and treatment of the breast and axilla Exclusion Criteria: * Clinically node negative breast cancer before NST * Bilateral invasive breast cancer * Neoadjuvant endocrine therapy * Distant metastases (including oligometastatic disease) * History of invasive breast cancer * Other malignancies, except for basal/squamous cell skin cancer, and in situ carcinoma of the cervix or breast * Axillary surgery or radiotherapy before NST (this includes SLNB prior to NST)
Conditions Advanced Malignant Neoplasm, Breast Canc...
Phase PHASE1, PHASE2
Enrollment 122
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

ATLAS-101 is a Phase I/II clinical trial of AMXI-5001 in adult participants with advanced malignancies who have previously failed other therapies. The study has two phases. The purpose of Phase I (Dose Escalation) is to confirm the appropriate treatment dose and Phase II (Dose Expansion) is to characterize the safety and efficacy of AMXI-5001.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: AMXI-5001:Dose Escalation Phase I — Phase I will enroll up to 70 participants to identify the Recommended Phase II daily dose in the treatment of various cancers and to characterize the safety, pharmacology, and clinical efficacy of AMXI-5001. AMXI-5001 is administered orally twice daily, with food. AMXI-5001 is administered weekly on a continuous 7-day schedule. Each cycle is 28 days.
  • Drug: AMXI-5001:Dose Expansion Phase II — Phase II will enroll up to 52 study participants to further characterize the safety, pharmacology, and clinical efficacy of AMXI-5001. AMXI-5001 is administered orally twice daily, with food. AMXI-5001 is administered weekly on a continuous 7-day schedule. Each cycle is 28 days.

Primary Outcomes

  • Determine the Maximum Tolerated Dose (MTD) (Approximately 12 months)
  • Determine the Recommended Phase 2 Dose (RP2D) for AMXI-5001 as monotherapy (Approximately 12 months)
  • Characterize safety profile of AMXI-5001 (Approximately 24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2020-08-12
Completion: 2026-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 122 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AtlasMedx, Incorporated
Principal Investigators:
  • Pamela Munster, MD (STUDY_DIRECTOR) - AtlasMedx, Incorporated
Contact Information
Study Contact:
Bonnie Wettersten, MS
(847) 644-9818
clinicaltrials@atlasmedx.com
Interventions
  • Drug: AMXI-5001:Dose Escalation Phase I — Phase I will enroll up to 70 participants to identify the Recommended Phase II daily dose in the treatment of various cancers and to characterize the safety, pharmacology, and clinical efficacy of AMXI-5001. AMXI-5001 is administered orally twice daily, with food. AMXI-5001 is administered weekly on a continuous 7-day schedule. Each cycle is 28 days.
  • Drug: AMXI-5001:Dose Expansion Phase II — Phase II will enroll up to 52 study participants to further characterize the safety, pharmacology, and clinical efficacy of AMXI-5001. AMXI-5001 is administered orally twice daily, with food. AMXI-5001 is administered weekly on a continuous 7-day schedule. Each cycle is 28 days.
Study Locations (4 sites)
University of California, Los Angles (UCLA) Department of Medicine - Hematology/Oncology, Los Angeles, California 90404 United States
Johns Hopkins, Baltimore, Maryland 21218 United States
SCRI Oncology Partners, Nashville, Tennessee 37203 United States
The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria (Key Factors): 1. Has pathologically confirmed advanced or metastatic malignancy characterized by one or more of the following: 1. Patient is intolerant of existing therapy(ies) known to provide clinical benefit for their condition 2. Malignancy is refractory to existing therapy(ies) known to potentially provide clinical benefit 3. Malignancy has progressed after standard therapy 2. Has evaluable or measurable tumor(s) in dose escalation by standard radiological and/or laboratory assessments as applicable to their malignancy. 3. Eastern Co-operative Oncology Group (ECOG) PS 0-1 4. Participant must be 18 years of age or older 5. Able to understand and sign consent Exclusion Criteria (Key Factors): 1. Receiving cancer treatment at the time of enrollment 2. Any clinically significant disease or condition affecting a major organ system 3. Significant cardiovascular disease or electrocardiogram (ECG) abnormalities 4. Use of a strong inhibitor or inducer of CYP3A4 within 7 days prior to start of study therapy and throughout the study (e.g., some antibiotics, antifungals, anticonvulsants, grapefruit) 5. Has had a previous (within 2 years) or has a current malignancy other than the target cancer
Conditions Esophageal Varices
Phase PHASE2, PHASE3
Enrollment 306
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Carvedilol versus endoscopic band ligation for primary prophylaxis of oesophageal variceal bleeding in cirrhotic patients with arterial hypertension

Design

Study type: Interventional Phases: Phase2, Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Drug: Carvedilol — Carvedilol
  • Procedure: Endoscopic band ligation — Endoscopic band ligation

Primary Outcomes

  • Number of patients with the first variceal bleeding within 1 year (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2, PHASE3
Status: Recruiting
Start Date: 2018-10-01
Completion: 2030-12-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 306 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sherief Abd-Elsalam
Principal Investigators:
  • Asem Elfert, Prof (STUDY_DIRECTOR) - Tanta University - Faculty of Medicine
  • Nabila Abd El-Nasser Abd El-Wahed El-Gazzar, ass. lect (PRINCIPAL_INVESTIGATOR) - Tanta University Faculty of medicine
Contact Information
Study Contact:
Sherief Abd-Elsalam, ass. prof.
00201147773440
sheriefabdelsalam@yahoo.com
Nabila el-gazzar, ass. lect.
00201147773440
sheriefabdelsalam@yahoo.com
sherief abd-elsalam, ass. prof
00201147773440
sheroefabdelsalam@yahoo.com
Sherief Abd-Elsalam
Interventions
  • Drug: Carvedilol — Carvedilol
  • Procedure: Endoscopic band ligation — Endoscopic band ligation
Study Locations (1 sites)
Sherief Abd-Elsalam, Tanta, Egypt
Eligibility Criteria
Inclusion Criteria: * • Aged \>18 years * Cirrhotic patients with arterial hypertension * Endoscopic evidence of medium/large-sized esophageal varices Exclusion Criteria: * • History of variceal bleeding or previous primary prevention of varices. * Portal vein thrombosis or previous porto-systemic shunts as TIPS. * Patients on drugs affecting portal pressure (beta blockers, nitrates). * Advanced cardiovascular disease including acute myocardial infarction, atrio-ventricular block, congestive heart failure, chronic peripheral ischemia, severe bradycardia. * Patients with severe respiratory diseases (COPD, bronchial asthma). * Uncontrolled diabetes mellitus * Renal impairment * Hepatocellular carcinoma * Allergy to carvedilol * Pregnancy or lactation
Conditions Triple Negative Breast Cancer
Phase PHASE2
Enrollment 286
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study will evaluate the efficacy and safety of antharcycline-based adjuvant chemotherapy compared with observation in triple negative breast cancer (TNBC) patients with residual invasive disease after platinum and taxanes based neoadjuvant chemotherapy.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Epirubicin or Pirarubicin — Epirubicin 80-90mg/m2 IV or Pirarubicin 50mg/m2 IV, q21d\*4cycls
  • Drug: Cyclophosphamide — Cyclophosphamide 600mg/m2 IV, q21d\*4cycls

Primary Outcomes

  • RFS (median 5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2020-02-01
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 286 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Chinese Academy of Medical Sciences
Principal Investigators:
  • Pin ZHANG, MD (PRINCIPAL_INVESTIGATOR) - Chinese Academy of Medical Sciences
Contact Information
Study Contact:
Pin ZHANG, MD
008601-87788120
Zhang_pin@sina.com
Pin ZHANG, MD
13701275563
Zhang_pin@sina.com
Cancer Hospital & Institute Chinese Academy of Medical Sciences (CAMS)
Interventions
  • Drug: Epirubicin or Pirarubicin — Epirubicin 80-90mg/m2 IV or Pirarubicin 50mg/m2 IV, q21d\*4cycls
  • Drug: Cyclophosphamide — Cyclophosphamide 600mg/m2 IV, q21d\*4cycls
Study Locations (1 sites)
Cancer Hospital & Institute Chinese Academy of Medical Sciences (CAMS), Beijing, Beijing Municipality 100021 China
Eligibility Criteria
Inclusion Criteria: * Patients with histologically confirmed invasive adenocarcinoma of the breast. * Triple negative breast cancer: hormone receptor negative (ER \< 10% and PgR \< 10%) and HER2 negative (IHC 0/1+ or ISH non-amplified), as defined by the local pathology laboratory. * Clinical stage at presentation: T1-4, N0-3, M0, with indications for neoadjuvant chemotherapy. * Patient must have received platinum and taxanes neoadjuvant chemotherapy for at least 4 cycles and no tumor progression occurred. * Patients should have undergone adequate tumor excision in the breast and lymph nodes after neoadjuvant chemotherapy. * Residual invasive disease must be ≥1cm in the breast, and/or have positive axillary lymph nodes observed on pathologic exam after neoadjuvant chemotherapy. * ECOG Performance Status: 0-1. * Patients without severe heart, lung, liver and kidney disease. * Adequate hematologic and end-organ function. * No more than 6 weeks may elapse between definitive breast surgery and randomization. Exclusion Criteria: * Previous neoadjuvant chemotherapy with anthracycline or other drugs (except platinum and taxanes). * Previous neoadjuvant chemotherapy with platinum or taxanes alone. * Patients have received other adjuvant therapy. * Comprehensive medical examinations have revealed distant metastases before randomization. * Patients who are not suitable for anthracycline evaluated by investigators. * Prior history of other malignancy (except carcinoma in situ).
Conditions Triple-negative Breast Cancer
Phase PHASE2
Enrollment 460
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Positive circulating tumor DNA(ctDNA) status is associated with worse prognosis in breast cancer, especially triple-negative breast cancer(TNBC). Our trial aims to improve the outcome of TNBC patients by using ctDNA to identify patients with high relapse risk. ctDNA positive patients will be randomized to receive boost therapy or standard therapy indicated in NCCN guidelines after NAC.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Tislelizumab — 200mg, q3w, for 1 year
  • Drug: capecitabine — 600-750 mg/m2 PO Bid,continuous, for 1 year

Primary Outcomes

  • 5 years Disease free survival(DFS) (60 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2020-08-03
Completion: 2032-08
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 460 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Principal Investigators:
  • Qiang Liu, MD (PRINCIPAL_INVESTIGATOR) - Sunyat-sen Memorial Hospital
Contact Information
Study Contact:
Shunying Li, MD
+86-15915939702
lishunying@foxmail.com
Yudong Li, MD
020-34071156
910870698@qq.com
shunying Li
+86-15915939702
lishunying@foxmail.com
Sunyat-sen Memorial Hospital
Interventions
  • Drug: Tislelizumab — 200mg, q3w, for 1 year
  • Drug: capecitabine — 600-750 mg/m2 PO Bid,continuous, for 1 year
Study Locations (1 sites)
Sunyat-sen Memorial Hospital, Guandong, Guangdong China
Eligibility Criteria
Inclusion Criteria: * Must have histologically or cytologically confirmed triple negative (ER-/PR-/HER2-) invasive breast cancer, clinical stage II-III at diagnosis (AJCC 6th edition) based on initial evaluation by physical examination and/or breast imaging prior to study registration.ER and PR will be considered negative if ≤ 1% of cells stain weakly positive. HER2 will be considered negative if scored 0 or 1+ by immunohistochemistry (IHC) or 2+ by IHC associated with a fluorescence in situ hybridization (FISH) ratio of \< 2.0 or \< 6 copies per cell. * Must receive preoperative (neoadjuvant) chemotherapy. NOTE: Acceptable preoperative regimens include those recommended by NCCN guidelines. Participants who received preoperative therapy as part of a clinical trial may enroll. * ctDNA positive at baseline, after NAC or after surgery * Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2 * Written informed consent to provide research blood samples and tumor samples * Patients must be willing to have frequent blood tests (every 3 months ) and receive a 12 month course of tislelizumab if randomised to tislelizumab treatment on ctDNA detection * No evidence of distant metastatic disease on staging scans conducted at the time of diagnosis Exclusion Criteria: * Previously participated in other interventional trials * Previous malignancy within 3 years of breast cancer diagnosis * Pregnancy or breastfeeding * No written consent * Unable to receive standard NAC and subsequent radiotherapy(if needed) * Active autoimmune disease